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In Brief
Rata et al. combine quantitative assays
with mathematical modeling to show that
hysteresis of the mitotic switch emerges
from mutual effects of Cdk1 and its
counteracting phosphatase, PP2A:B55,
on each other’s auto-activation loops.
Their work also reveals an intermediate
but hidden steady state between
interphase and M phase..
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Distinct protein phosphorylation levels in interphase
andM phase require tight regulation of Cdk1 activity
[1, 2]. A bistable switch, based on positive feedback
in the Cdk1 activation loop, has been proposed
to generate different thresholds for transitions be-
tween these cell-cycle states [3–5]. Recently, the
activity of the major Cdk1-counteracting phospha-
tase, PP2A:B55, has also been found to be bistable
due to Greatwall kinase-dependent regulation [6].
However, the interplay of the regulation of Cdk1
and PP2A:B55 in vivo remains unexplored. Here,
we combine quantitative cell biology assays with
mathematical modeling to explore the interplay of
mitotic kinase activation and phosphatase inactiva-
tion in human cells. By measuring mitotic entry and
exit thresholds using ATP-analog-sensitive Cdk1
mutants, we find evidence that the mitotic switch
displays hysteresis and bistability, responding
differentially to Cdk1 inhibition in the mitotic and
interphase states. Cdk1 activation by Wee1/Cdc25
feedback loops and PP2A:B55 inactivation by
Greatwall independently contributes to this hyster-
etic switch system. However, elimination of both
Cdk1 and PP2A:B55 inactivation fully abrogates
bistability, suggesting that hysteresis is an emer-
gent property of mutual inhibition between the
Cdk1 and PP2A:B55 feedback loops. Our model of
the two interlinked feedback systems predicts an
intermediate but hidden steady state between
interphase and M phase. This could be verified
experimentally by Cdk1 inhibition during mitotic en-
try, supporting the predictive value of our model.
Furthermore, we demonstrate that dual inhibition
of Wee1 and Gwl kinases causes loss of cell-cycle3824 Current Biology 28, 3824–3832, December 3, 2018 ª 2018 The
This is an open access article under the CC BY license (http://creativememory and synthetic lethality, which could be
further exploited therapeutically.
RESULTS AND DISCUSSION
When cells enter M phase, a burst of morphological changes
occurs, resulting in a profound reorganization of various cellular
compartments in preparation for chromosome segregation and
cell division. These changes are driven by Ser/Thr phosphoryla-
tion of over a thousand proteins, predominantly by cyclin-depen-
dent kinase 1 (Cdk1) in complex with cyclin B (CycB) [7, 8]. Thus,
Cdk1:CycB activation is the crucial event leading to mitosis,
and the dynamics of this process have long been a focus of
theoretical exploration. A key activation step of this kinase is
the removal of Wee1/Myt1-dependent inhibitory phosphoryla-
tions of Cdk1 at Thr14/Tyr15 by Cdc25 phosphatases. Both
inhibitory kinases and activating phosphatases are linked via
positive feedback with Cdk1, creating bistability in Cdk1 activity
with respect to total CycB (Figure 1A) [3]. The bistable switch,
well-known in engineering [9, 10], creates two distinct states,
corresponding to interphase and M phase, without allowing the
cell to come to rest in intermediate transitional states. There
are distinct thresholds for mitotic entry and mitotic exit, so that
once a cell accumulates enough CycB and commits to mitotic
entry, it will only exit mitosis at a lower CycB level. This difference
in thresholds provides robustness of the M phase state and pre-
vents the cell from flipping back to the interphase state in the
noisy cellular environment. Bistability of the mitotic switch sys-
tem was confirmed in Xenopus extracts [4, 5] but has not
been directly tested in intact mammalian cells. Moreover, the
original Novak/Tyson mitotic switchmodel presumed a constitu-
tive Cdk1-counteracting phosphatase, whose identity was un-
known at the time. In recent years, however, it has become
apparent that Cdk1-counteracting protein phosphatases (PP1
and PP2A) are also under stringent regulation [11, 12]. The
best example for this is PP2A with its B55 regulatory subunit
(PP2A:B55), which is tightly regulated by Greatwall (Gwl) kinase
[13] via its substrates ENSA and ARPP19 that become potentAuthors. Published by Elsevier Ltd.
commons.org/licenses/by/4.0/).
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Figure 1. Bistable Switches of Mitotic Control
(A–C) Schematic signal-response (SR) diagram for Cdk1 auto-activation (A), PP2A:B55 feedback regulation (B), and mitotic substrate phosphorylation by
interlinked kinase–phosphatase switches (C).
(D)Model of the hysteresis assay based onCdk1 inhibition. TheCdk1 inhibitor shifts the SR curve to the right in a concentration-dependentmanner: more inhibitor
is required to induce mitotic exit (right curve) than to block mitotic entry (middle curve).
(E) Summary: Cdk1 inhibitor blocks mitotic entry and promotes mitotic exit.PP2A:B55 inhibitors upon phosphorylation [14, 15]. Gwl itself is
activated by Cdk1-dependent phosphorylation [16], which is
reversed by PP1 [17–19] and PP2A:B55 [6, 20], and the latter
creates a mutual antagonism. Reconstitution of the Gwl-ENSA-
PP2A:B55 pathway in vitro confirmed these interactions and re-
vealed that PP2A:B55 has a bistable activity with respect to
Cdk1 activity [6] (Figure 1B). What remains to be determined is
how these two bistable switches of Cdk1:CycB and PP2A:B55
are interlinked during interphase–M phase transitions in the
context of the somatic mammalian cell cycle. Given that Cdk1 in-
fluences PP2A:B55 activity via Gwl and PP2A:B55 negatively
regulates Cdk1 via Wee1 and Cdc25 [21], one can imagine that
the two feedback systems might reinforce each other, thereby
increasing the robust separation of interphase and M phase
states (Figure 1C). However, Gwl depletion and genetic deletion
in mammalian cells results only in minor delays in the G2/M tran-
sition and does not interfere with establishing the mitotic state
and initiating cell division [22–24]. Thus, the precise contributions
of the Cdk1 activation and PP2A:B55 inhibition feedback
network to the G2/M switch system remain to be determined.
We set out to establish a quantitative assay for interphase–M
phase bistability in human cells. A key feature of mitotic bistabil-
ity is hysteresis—mitotic entry requires a larger cyclin B levelthan that required to block the reverse transition at mitotic exit
(Figure 1C). We reasoned that hysteresis of mitotic transitions
could also be quantitatively assessed by exposing cells to
increased concentrations of a Cdk1 inhibitor that shifts the
S-shaped substrate phosphorylation curve to the right (Fig-
ure 1D). If the mitotic switch is bistable and shows hysteresis,
the threshold concentration of Cdk1 inhibitor required to block
mitotic entry (qentry) should be smaller than the one needed to
induce mitotic exit (qexit) at a given cyclin B level (Figure 1D).
To test this prediction, we used an analog-sensitive mutation
in Cdk1 (cdk1as) that allows specific and reversible inhibition
with the ATP analog 1NM-PP1 [25, 26] (Figures 1E, S1A, and
S1B). Thus, measuring the 1NM-PP1 concentrations required
to prevent entry into mitosis and to trigger mitotic exit should
allow us to determine qentry and qexit. To simplify this assay, we
performed G2/M synchronization of cdk1as cells (i.e., arresting
them in G2 by 1NM-PP1 treatment and releasing them from
G2 into mitosis) and used proteasome inhibition throughout the
experiment to ensure constant cyclin B levels (see Figure 2A
for experimental setup and Figure 2B and Video S1 for an
example of a mitotic entry and exit experiment).
These highly synchronous mitotic entry and exit experiments
allow a quantitative assessment of the Cdk1 inhibitor thresholdsCurrent Biology 28, 3824–3832, December 3, 2018 3825
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Figure 2. Hysteresis of Mammalian Mitotic Control
(A) Experimental protocol to measure threshold 1NM-PP1 concentrations at constant CycB levels in cdk1as cells (see Figure S1 for characterization of cdk1as
cells and STAR Methods for details of how they were generated).
(B) Still images from time-lapse videos (see also Video S1) of HeLa cdk1as cells released from 20-hr 1NM-PP1 arrest (entry, top two panels) or treated with 2 mM
1NM-PP1 90 min after mitotic arrest in MG132 (exit, bottom two panels). Time in minutes from release into MG132 (top panels) or from 1NM-PP1 add-back
(bottom panels) is shown. Scale bars indicate 10 mm.
(C) Galleries of nuclei from HeLa cdk1as cells, imaged 4 hr after entry and exit treatments (1NM-PP1 concentrations in mM as indicated above the panels). For
each panel, one hundred nuclei were randomly chosen by Olympus SCANR software. Interphase nuclei appear rounded and enlarged; mitotic nuclei are
rod-shaped and condensed. The red lines indicate the borders upon which 1NM-PP1 is becoming active for either entry or exit.
(D) Quantifications of entry and exit experiments in HeLa cdk1as cells (see Figure S2 for similar results with U2OS cdk1as cells). The values are means of three
biological repeats (N = 100 per repeat), and error bars indicate SD.
(E) Temporal dynamics of mitotic entry at increasing 1NM-PP1 concentrations from live-cell imaging analysis.
(F) Levels ofmitotic cyclins in G2- andM-arrested cells analyzed by immuno-blotting with indicated antibodies. Each panel shows four steps of a serial 1:1 dilution
of extracts.
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on these cell-cycle transitions. To obtain these measurements,
we released HeLa cdk1as cells into increasing concentrations
of 1NM-PP1 and tested for mitotic entry. For exit experiments,
cells were released into 1NMPP-free medium and subsequently
forced out of the mitotic state by increasing 1NM-PP1 concen-
trations. To assess the percentage of cells in mitosis and inter-
phase following a dose-response curve with 1NM-PP1, we
used an endpoint assay 4 hr after 1NM-PP1 addition and scored
for interphase or mitosis by the morphology of Hoechst-stained
DNA as shown in Figure 2C. Representative galleries of Hoechst-
stained single cells show a clear threshold to block entry at
0.2 mM 1NM-PP1. In contrast, a similar induction of mitotic exit
was only achieved at doses between 0.4 and 0.8 mM 1NM-
PP1, suggesting a 2- to 4-fold change in entry and exit thresh-
olds. Quantification of these data revealed a half-maximal
inhibitory concentration (IC50) change from 143 nM to 573 nM
between entry and exit experiments (Figure 2D). A similar result
was also obtained in U2OS cdk1as cells (Figure S2A). We also
followed cells enteringmitosis by live-cell imaging and quantified
the percentage of mitotic cells over time using an automated
detection algorithm (see STAR Methods). The rate of entry into
mitosis declined with increasing inhibitor concentrations (Fig-
ure 2E), with the mitotic population reaching saturation 2 or
3 hr following 1NM-PP1 addition for each condition. We noted
that cells appeared less sensitive to 1NM-PP1 when imaged
on the fluorescence microscope, suggesting that 1NM-PP1
might be affected by light exposure. This made a direct compar-
ison between endpoint and live-cell assays difficult, but we pro-
ceeded with both strategies to confirm thresholds and satura-
tion. The interpretation of these experiments requires identical
mitotic cyclin levels during mitotic entry and exit experiments,
and this was verified by immuno-blotting (Figure 2F).
Based on the hysteresis assay shown in Figure 2, we aimed to
establish amathematical model to simulate this experiment. This
model was designed to test the contribution of phosphatase and
kinase regulation to bistability and to perform parameter fitting to
satisfy all experimental conditions. To this end, we used non-
linear ordinary differential equations describing the feedback
regulation of Cdk1 and PP2A:B55 (see Figure 3A for the basic
wiring diagram; for details on the equations and parameters,
see STAR Methods). To obtain experimental parameters for
this model and to determine the contribution of individual
feedbacks to bistability, we measured the hysteresis effect in
HeLa cdk1as cells following Wee1 inhibition and Gwl depletion
(Figure S3A) both individually and in combination (Figure 3B).
Wee1 inhibition only had a mild effect on hysteresis, shifting
the mitotic entry curve toward increased 1NM-PP1 doses
(midpoint around 300 nM), and did not significantly affect the
mitotic exit curve. Gwl depletion had a more pronounced effect,
shifting both entry and exit curves toward lower 1NM-PP1
(midpoints around 67 nM and 92 nM, respectively; Figures S3B
and S3C). The effect of Gwl depletion on the entry threshold
was partially reverted by Wee1 inhibition, and we observed a
complete collapse of hysteresis in these conditions (IC50s for en-
try and exit at 147 nM and 150 nM, respectively; Figures 3B and
S3C). Time course experiments of mitotic entry under the various
conditions confirmed that saturation was reached between three
to 4 hr (Figure S3D). These data suggest that both PP2A:B55 and
Cdk1 autoregulation contribute to bistability, which is only lost ifboth feedback systems become compromised. If the regulation
of Cdk1 did not contribute to the bistability of the system, we
would not expect to observe hysteresis with Gwl depletion,
and if the regulation of PP2A:B55 did not contribute to the overall
bistability, we would not expect to observe hysteresis with Wee1
inhibition.
The kinetic constants of the model were determined by fitting
themodel to the experimental data, with initial estimates from the
literature, where available [27]. To determine whether a cell is in
interphase or M phase, we included a generic Cdk1/PP2A:B55
substrate in the model and set a threshold phosphorylation level
for the interphase-M phase boundary. Based on immunofluores-
cence assays (see Figure 4E), we attributed this threshold to
be 30% maximal substrate phosphorylation. Plotting the pre-
dicted steady-state phosphorylation level of the generic Cdk1/
PP2A:B55 substrate against 1NM-PP1 concentration (Figure 3C)
suggests that themodel captures the salient features of the data.
There is a clear difference between the 1NM-PP1 doses needed
to block mitotic entry and forcing mitotic exit in the control case.
When addition of Wee1 inhibitor is simulated, the 1NM-PP1
threshold of mitotic entry is increased, and that of exit is
unchanged. This latter feature of the model requires that
PP2A:B55 inhibits amplification of Cdk1 activity, which together
with Cdk1-dependent Greatwall activation makes the kinase–
phosphatase feedback systemsmutually inhibitory, as proposed
on Figure 1C. The hysteresis in this case is due to bistable
PP2A:B55 activity (Figure S3E). With Gwl depletion, the model
has reduced bistability and both thresholds are reduced.
PP2A:B55 is modeled to be constitutively active with this pertur-
bation and dephosphorylates the regulators of Cdk1 and the
generic Cdk1/PP2A:B55 substrate. The hysteresis in this case
is due to bistable Cdk1 activity (Figure S3E). A combination of
Wee1 inhibition and Gwl depletion eliminates bistability in the
model. We also simulated variance among the population
of cells, assuming a log-normal distribution of total cyclin B
(Figure S3F), with good agreement to the experimental data
(Figure 3D).
A surprising prediction of our mathematical model for the
G2/M switch is the existence of a third stable steady state in be-
tween interphase and mitosis. This steady state did not appear
in previous models but emerged as a feature of our model after
fitting to all experimental conditions. The state is not observable
during normal mitotic progression; therefore, using the model,
we devised an experiment to test its existence. Our model sug-
gests that cells can be captured in this hypothetical intermedi-
ate stable state if Cdk1 activity is partially reduced during the
G2-M transition (Figure S4A). To test this prediction, we used
endogenously tagged CyclinB1-mVenus (Figure S4B) as a pro-
phase marker (i.e., nuclear localization of cyclin B and intact nu-
clear envelope [NE]) and followed cells that were released from
1NM-PP1 and re-exposed to increasing 1NM-PP1 concentra-
tions 25 min after release (Figure 4A). Prophase cells with nu-
clear cyclin B that lost sufficient amounts of Cdk1 activity are
expected to re-export cyclin B to the cytoplasm, as previously
reported [28] (Figure 4B, left panels), and insufficient Cdk1 inhi-
bition would allow the cells to continue to M phase marked by
nuclear envelope breakdown (NEBD) (Figure 4B, middle panels).
We expected from the model that a fraction of cells should
remain in prophase in this experiment, and we could indeedCurrent Biology 28, 3824–3832, December 3, 2018 3827
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Figure 3. Contribution of Cdk1 and PP2A:B55 Feedbacks to Hysteresis
(A) Wiring diagram of the mitotic switch that forms the basis of the modeling for this paper.
(B) Percentage of cells entering into (red) and staying in (blue) mitosis at different Cdk1 inhibitor concentrations. Control (left column), Wee1-inhibited (second
column), Gwl-depleted (third column; see Figure S3A for confirmation of depletion and Figure S3B for a higher resolution of 1NM-PP1 concentrations for this
condition), and bothWee1-inhibited and Gwl-depleted (right column) cells are shown, with means of 3 or 4 biological repeats (N = 100 per repeat) and errors bars
indicating SD (see Figure S3C for comparison of IC50s for the different experimental conditions and Figure S3D for time course data).
(C) Signal-response curves for mitotic substrate phosphorylation in single cells as a function of inhibitor concentration. Steady-state substrate phosphorylation is
high (red), low (blue), or intermediate (orange).
(D) Simulated population response of mitotic cells assuming log-normal CycB distribution among individual cells (see Figure S3F for our estimation of cyclin B
concentration in the population, on which this model was based).observe cells that kept nuclear cyclin B and remained rounded
up but did not undergo NEBD (Figure 4B, right panels; see also
Video S2).3828 Current Biology 28, 3824–3832, December 3, 2018We quantified the nuclear-cytoplasmic ratio of cyclin B in cells
with intact nuclei. This resulted in a clear separation in a ‘‘back to
G2 (i.e. loss of nuclear cyclin B)’’ versus ‘‘prophase (i.e. cyclin B
A B
C D E F
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J
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Figure 4. Testing Predictions of the Model
(A) Explanation of the synchronization protocol to obtain cells arrested in prophase (see Figure S4A for a simulation of this experiment based on the model).
(B) Images of cyclin B1-GFP-tagged HeLa cdk1as cells released from 1NM-PP1 arrest and retreated with 1 mM1NM-PP1 25min after release (see Figure S4B for
characterization of the GFP knockin cells). Time after re-addition of 1NM-PP1 is indicated in minutes; scale bars correspond to 20 mm. Left panels show cells
moving back to G2 (chromosome decondenses and cyclin B is exported and cells flatten); middle panels show cells moving to mitotic arrest (chromosome
condensation, nuclear envelope breakdown, and cell rounding); right panels show cells that remain in prophase (chromosomes partially condensed, cyclin B
remains nuclear, and cells remain rounded up). See also Video S2.
(C) Measurements of cytoplasmic versus nuclear cyclin B1 ratio in single cells (top panels). Quantification of cell-cycle states in cells treated as described in (B)
4 hr after 1NM-PP1 addition (bottom). N > 20 in three independent experiments, error bars indicate SD.
(D) Representative images of cells fixed 4 hr after 1NM-PP1 re-addition and stained by immuno-fluorescence with indicated antibodies. Scale bar, 10 mM.
(E) Quantification of Cdk1 substrate phosphorylation, Cdk1 Y15 phosphorylation, and nuclear surface of cells in the G2/M and prophase steady states (data are
from three independent experiments; N > 40 per experimental repeat; error bars indicate SD; p values were assessed using an independent two-sample t test;
significant [***p < 0.001; *p < 0.05] p values are indicated).
(F) Images of HeLa cells progressing throughmitosis after combined Gwl depletion andWee1 inhibition. Time intervals are indicated in hr:min; scale bars indicate
10 mm; see also Videos S3 and S4.
(legend continued on next page)
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remains nuclear)’’ population (Figure 4C, top two panels). The
prophase population was only observed when Cdk1 inhibitor
was added back following release from the G2 arrest and
increased with increasing inhibitor dose to about 10% at 1 mM
1NM-PP1 (Figure 4C, bottom panel). We further characterized
this prophase steady state by immuno-fluorescence (Figure 4D),
probing for cyclin B, lamin, Cdk1 substrate phosphorylation, and
Cdk1Y15phosphorylation. In cell populations thatwere released
from 1NM-PP1 and re-treated with 1 mM 1NM-PP1, we could
readily identify a population of prophase cells 4 hr after release
from theG2 arrest, andwe did not observe similar prophase cells
4 hr after release without re-addition of 1NM-PP1. These cells
were characterized by nuclear cyclin B, partially condensed
DNA, yet intact nuclear envelope as judged by lamin B staining
(Figure 4D). Compared with G2 and M phase cells, the prophase
cells showed intermediate levels of Cdk1 activity and Y15
dephosphorylation, as predicted by the model, and displayed a
decreased nuclear area, suggesting an intermediate state of
chromosomecompaction (Figure 4D; quantification in Figure 4E).
We next aimed to investigate whether loss of bistability has
consequences for mitotic progression and cell proliferation
that could ultimately be of therapeutic benefit. We first analyzed
the effects of loss of combined Gwl and Wee1 inhibition on
mitotic progression in asynchronously dividing HeLa cdk1as
cells. A large fraction of cells lacking both Gwl and Wee1 activity
readily entered mitosis but subsequently failed to stabilize the
metaphase state, reverting to an interphase state without any
visible attempt at chromosome segregation and cytokinesis (Fig-
ure 4F; quantification in Figure 4G; see Video S3). This response
was unique to the combined loss of the Gwl/Wee1 condition and
not observed in the controls that all exited mitosis with chromo-
some segregation and cleavage furrow formation (Figure 4H;
Video S4). This exit was also in marked difference to spindle
assembly checkpoint slippage, in which Gwl-depleted cells left
the mitotic state after attempting chromosome segregation
and cytokinesis (Video S4). This result suggests that loss of bist-
ability does, indeed, result in a failure to stabilize the metaphase
state and also in a failure to initiate progression through mitosis
toward cell division and G1. To investigate whether the synergis-
tic effects of Gwl/Wee1 double inactivation could be used to
inhibit cell proliferation in a therapeutic setting, we analyzed
cell-cycle progression and proliferation in the triple-negative
breast cancer cell line MDA MB 231, where Gwl is depleted via
doxycycline-inducible Cas9/gRNA [29] (Figure S4C). Edu label-
ing and fluorescence-activated cell sorting (FACS) analysis
showed a significant reduction in the replicating S phase popu-
lation 24 hr after treatment with 0.25 and 0.5 mM of the Wee1 in-(G) Quantification of mitotic phenotypes from live-cell imaging in HeLa cells.
(H) Cell-cycle profiles of MDA MB 231 cells following inducible Gwl knockout (se
(replicating population) and PI (DNA content) staining and FACS analysis.
(I) Average values for Edu-positive and negative S phase populations of MDA M
independent experiments; N = 10,000 per experiment; error bars indicate SD (se
(J) Proliferation assays following increasing time ofWee1 inhibition inMDAMB 231
on Hoechst staining and nuclear segmentation 6 days after MK1775 pulse treatm
error bars indicate SD. p values were assessed using an independent two-sam
indicated.
(K) Colony-formation assays in MDA MB 231 cells following Ctr and Gwl gRNA/
trations. 5,000 cells were plated into each 6-well plate and stained and imaged 2
See also Figure S4.
3830 Current Biology 28, 3824–3832, December 3, 2018hibitor MK1775 when Gwl was co-depleted (Figures 4H, 4I, and
S4D). A 24-hr pulse treatment with the Wee1 inhibitor also signif-
icantly reduced cell proliferation as judged by cell counts 6 days
after treatment (Figure 4J) and colony formation assays (Fig-
ure 4K). This synergy dissipated in longer term treatments with
Wee1 inhibitors where the toxicity of Wee1 inhibition alone
appeared to become dominant (Figure 4J).
Our results demonstrate that the mitotic switch in somatic
human cells is bistable, clarify how Cdk1 and PP2A regulation
contribute to the establishment of this switch, and provide a
comprehensive quantitative model for mitotic transitions. Our
observations suggesting that two interlinked bistable switches
work together to stably separate interphase and M phase could
reflect a paradigm also acting in other cellular switch systems
[30]. The network architecture of this switch allows transitions
to be made between states with maximum theoretical efficiency
[31]. Our model is of predictive value as demonstrated by the
discovery and verification of a new steady state in prophase.
Although this steady state appears to be an integral feature of
the dynamical switch system, it has not to our knowledge been
described previously, and its physiological relevance remains
to be addressed. Indeed, RPE-1 cells have been reported to stall
in late G2 phase with nuclear cyclin B following DNA damage for
several hours before Cyclin degradation and exit into senes-
cence [32, 33]. It is tempting to speculate that this arrest point
may be related to the prophase steady state observed in our
study. Our results also suggest that abrogating bistability leads
to an unstable mitotic state and to loss of the irreversible
progression toward cell division. Accordingly, double inhibition
of both Gwl and Wee1 causes an additive effect on proliferation
in breast cancer cells (Figures 4H–4K). This synthetic lethality
due to loss of bistability could be exploited therapeutically
once specific Gwl inhibitors become available.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
General cell line culture conditions
U2OS, HeLa and MDA MB 231 cells were cultured in Dulbecco’s modified Eagle Medium supplemented with 10% FCS, 2 mM
L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin in a 37C, 5% CO2 incubator.
HeLa cdk1as cells (Human cervical cancer cell line, female)
HeLa Cdk1as were established by stably expressing Cdk1-F80G-myc using a T2A linked puromycin selection cassette cloned into
pcDNA3.1, in HeLaMKK1 cells (A gift fromPatrickMeraldi [34],). EndogenousCdk1was then removed byCRISPR nuclease targeting
using pX459 Cas9T2Apuro [35], target sequence (50ATTTCCCGAATTGCAGTACTAGG 30).
HeLa cdk1as cells with GFP tagged endogenous Cyclin B
The Cyclin B1 gRNA was designed in the vicinity of the C-terminal of the coding sequence of Cyclin B1 using Benchling CRISPR tool
(https://benchling.com/). The sequences 50 ACTAGTTCAAGAT-TTAGCCA 30 were introduced into the vector pSpCas9(BB)-2A-Puro
(PX459, acquired from Feng Zhang via Addgene (plasmid # 48139)) V2.0 following the protocol described in [36]. To make the target-
ing template, Gibson assembly was used to assemble into NotI-digested pAAV-CMV vector (gift from Stephan Geley, University of
Innsbruck, Austria) the fragments in the following order: the upstream targeting region (954bp), a linker (50 CGCCTCAGCGGCAT
CAGCTGCAGGAGCTGGAGGTGCATCTGGCTCAGCGG-CAGG 30), mEmerald, P2A-neomycin and the downstream targeting
region (824bp). To get CRISPR-resistant constructs, the sequences ACTAGTTCAAGATTTAGCCAAGG were mutated to AtTAGTc
CAgGAccTAGCtAAaG. Mutations (lowercase letters) are silent and preferential codon usage was taken into account. Cas9-gRNA
expressing and targeting plasmid were co-transfected in HeLa cdk1as cells using Fugene (Promega) according to manufacturers
recommended protocol and integrants were selected in 200 mg/ml G418. And confirmed by Immuno-blotting.
U2OS cdk1as cells (Human bone osteosarcoma epithelial cell, female)
U2OS cells were obtained from the GDSC tisscue culture facility and previously verified by ACTT’s cell line authentication service.
XLcdk1as expression and knock out of endogenous Cdk1 was established as for HeLa cdk1as cells, except that
50AATCCATGTACTGACCAGGAGGG 30 was used as the gRNA target sequence.
MDAMB231Cells expressing inducible Greatwall-Cas9-gRNA (Human triple negative breast cancer cell line, female)
These triple negative breast cancer cells express a lentiviral Tet inducible Cas9/gRNA targeting Greatwall [29]. Induction of Cas9 by
1mg/ml Doxycyclin results in Greatwall knock outs and depletion of the protein within 3 days (see Immunoblot confirmation in
Figure S4).
METHOD DETAILS
Modeling of mitotic entry and exit
We used nonlinear ordinary differential equations (ODEs) to describe the kinetics of Cdk1:CycB and PP2A:B55 regulation. The ODEs
describe the rate of change of the concentration of proteins in the regulatory pathways with respect to time. We used exclusively law
of mass action kinetics, approximating enzyme catalyzed reactions by second-order kinetics, ignoring the explicit enzyme–substrate
complex (except for pENSA bound to PP2A:B55). Rate constants and rate functions are abbreviated by ‘k’ and ‘V’, respectively, with
subscripts referring to the enzyme and the substrate of the reaction.
Based on the experimental data the model should have some fundamental qualitative features. There should be bistability in the
control, Wee1 inhibition, and Gwl depletion cases, with reduced bistability in the latter two. Bistabilty should be diminished in the
combined Wee1 inhibition and Gwl depletion case.
Based on the 20 hour G2 block and use of proteasome inhibitor, we can assume that the protein levels are unchanged following the
G2 block. This is particularly important for CycB, as well as proteins that are normally degraded during mitotic progression.
A generic substrate is phosphorylated by Cdk1:CycB and dephosphorylated by PP2A:B55:
d½Subp
dt
= kCdk1;Sub,VCdk1,ð½SubTot  ½SubpÞ  kB55;Sub,½PP2AB55,½Subp
Cdk1:CycB is dephosphorylated (and activated) by Cdc25 and phosphorylated (and inactivated) by Wee1:
d½CycB : Cdk1
dt
=VCdc25,ð½CycBTot  ½CycB : Cdk1Þ  VWee1,½CycB : Cdk1
PP1 is inactivated when phosphorylated by Cdk1. PP1 reactivates itself in trans:
d½PP1
dt
= ðkaPP1 + kaPP1a,½PP1Þ,ð½PP1Tot  ½PP1Þ  ðkiPP1 + kCdk1;PP1,VCdk1Þ,½PP1e2 Current Biology 28, 3824–3832.e1–e6, December 3, 2018
ENSA is phosphorylated by active Gwl and dephosphorylated by B55 when in complex with the phosphatase:
d½pENSATot
dt
=VGwl,ð½ENSATot  ½pENSATotÞ  kcatB55,½pENSA : B55
Gwl is phosphorylated (and activated) by Cdk1:CycB and Cdk2:CycA. Gwl is dephosphorylated (and inactivated) by PP2A:B55, PP1,
and a constitutive phosphatase:
d½Gwlp
dt
= ðkCdk1;Gwl,VCdk1 + kCdk2;Gwl,½Cdk2TotÞ,ð½GwlTot  ½GwlpÞ  ðkB55;Gwl,½PP2AB55+ kPP1;Gwl,½PP1+ kPPX;GwlÞ,½Gwlp
PP2A:B55 associates with phosphorylated ENSA, titrating the phosphatase away from other substrates. PP2A:B55 dephosphory-
lates pENSA to which it is bound:
d½PP2AB55
dt
= ðkdis + kcatB55Þ,½pENSA : B55  kass,½PP2AB55,ð½pENSATot  ½pENSA : B55Þ
Wee1 is phosphorylated (and inactivated) by Cdk1:CycB and Cdk2:CycA. Wee1 is dephosphorylated (and activated) by PP2A:B55
and a constitutive phosphatase:
d½Wee1
dt
= ðkPPX;Y15 + kBB5;Wee1,½PP2AB55Þ,½Wee1p  ðkCdk1;Wee1,VCdk1 + kCdk2;Wee1,½Cdk2TotÞ,½Wee1
We include a second inhibitory phosphorylation of Wee1 with the same rate constants for each phosphosite [37]:
d½Wee1pp
dt
= ðkCdk1;Wee1,VCdk1 + kCdk2;Wee1,½Cdk2TotÞ,½Wee1p  ðkPPX;Y15 + kB55;Wee1,½PP2AB55Þ,½Wee1pp
Cdc25 is phosphorylated (and activated) by Cdk1:CycB and Cdk2:CycA. Cdc25 is dephosphorylated (and inactivated) by PP2A:B55
and a constitutive phosphatase:
d½Cdc25
dt
= ðkPPX;Y15 + kB55;Cdc25,½PP2AB55Þ,½Cdc25p  ðkCdk1;Cdc25,VCdk1 + kCdk2;Cdc25,½CycATotÞ,½Cdc25
We include a second activating phosphorylation of Cdc25 [38] with the same rate constants for each phosphosite:
d½Cdc25pp
dt
= ðkCdk1;Cdc25,VCdk1 + kCdk2;Cdc25,½CycATotÞ,½Cdc25p  ðkPPX;Y15 + kB55;Cdc25,½PP2AB55Þ,½Cdc25pp
Cdk1 is inhibited by 1NM-PP1 (InhCdk1), which in steady state provides the following rate function:
VCdk1 =
½CycB : Cdk1
1+
InhCdk1
Kd
Conservation of total PP2A:B55: ½pENSA : B55 = ½B55Tot  ½PP2AB55
Conservation of Wee1: ½Wee1p = ½Wee1Tot  ½Wee1  ½Wee1pp
Conservation of Cdc25: ½Cdc25p = ½Cdc25Tot  ½Cdc25  ½Cdc25pp
Wee1 and Cdc25 activities (rate functions) are the sum of their less- and more-active forms:
VWee1 = kWee1S,ð½Wee1Tot  ½Wee1Þ+ kWee1F,½Wee1VCdc25 = kCdc25S$ Cdc25Tot½   Cdc25pp½ ð Þ+ kCdc25F$ Cdc25pp½ 
Gwl rate function depends on the phosphorylated form: VGwl = kGwl;ENSA,½Gwlp
This system of differential and algebraic equations was solved with numerical integration, giving the protein concentrations in time.
The model output can be interpreted with bifurcation diagrams, which depict the steady state response of a variable with respect to
a changing parameter value. This allows for comparison with the end-point experiments in Figure 3B. For Wee1 inhibition, set the
parameters kWee1S and kWee1F to 0. For Gwl siRNA, set the ½GwlTot parameter to 0. For Figure S4A set InhCdk 1 = 0.5 mM.
The experimental results are presented as ‘mitotic cells’, whereas the model has ‘substrate phosphorylation’. To directly compare
the two, we chose a 30% maximal substrate phosphorylation threshold for the mitotic state, which was based on our immuno-fluo-
rescence quantifications. The bifurcation diagrams in Figure 3C can be compared with the experimental results in this way.
Mathematical modeling of the variation within a population of cells
The nonlinear ordinary differential equations described above can describe the behavior of a single cell. To capture the variation
observed between cells in the experiments heterogeneity has to be introduced into the model. We decided to simulate a log-normal
distribution of total CycB level for the population of cells (Figure S3F) based on [39] with median 8.18 AU and standard deviation
4.31 AU. Since the total CycB level is assumed to remain constant after release from the G2 block, this involved changing just
one parameter for each simulation. Simulating the experimental protocol in silico gave the results in Figure 3D, after parameter fitting.Current Biology 28, 3824–3832.e1–e6, December 3, 2018 e3
Estimation of the kinetic parameters of the model
Since the intracellular concentrations of proteins are largely unknown (with few exceptions), we have chosen the total concentrations
of the following proteins (CycA:Cdk2, PP1, ENSA, Gwl, Wee1, Cdc25 and Sub) as one arbitrary unit, except B55Tot = 0.25 and Cy-
cBTot = 8.18 (see below). Our zero- and second-order rate constants can be immediately converted into nM min
-1 and nM-1 min-1
dimensions in view of protein concentrations in nM. We built a customised objective function within the parameter fitting routine
MEIGO [40] to parameterise the model. An initial parameterisation was performed using the 50% levels for each of the four exper-
imental conditions. This determined a median cyclin B level. Next, the log-normal cyclin B distribution was used to fit all of the exper-
imental data, and this time the variance of the cyclin B distribution was fitted.We used the values in [27] as initial values for the binding
and activity of PP2A:B55 toward pENSA. After fitting, the catalytic and association (after scaling) values were within 3–5-fold of the
literature values. All the parameters and initial conditions are in the tables below.
Parameter values used in the model.Name Description Value
InhCdk1 Level of 1NM-PP1 added 0–2 mM
kaPP1 Constitutive dephosphorylation and thereby activation of PP1 0.01 min
-1
kaPP1a Dephosphorylation of PP1 by dephosphorylated PP1 in trans 0.70 min
-1
kiPP1 Constitutive phosphorylation and hence inactivation of PP1 0.002 min
-1
kCdk1;PP1 Phosphorylation of PP1 by Cdk1:CycB 0.75 min
-1
kPP1;Gwl Dephosphorylation of Gwl by PP1 18.47 min
-1
kass Association of phosphorylated ENSA with PP2A:B55 617 min
-1
kdis Dissociation of the pENSA:PP2A:B55 complex 0.009 min
-1
kcatB55 Dephosphorylation of pENSA when in complex with PP2A:B55 1 min
-1
kGwl;ENSA Phosphorylation of ENSA by Gwl 21 min
-1
kPPX;Gwl Basal dephosphorylation of Gwl 0.16 min
-1
kCdk1;Sub Phosphorylation of the substrate by Cdk1:CycB 0.008 min
-1
kCdk1;Gwl Phosphorylation of Gwl by Cdk1:CycB 0.24 min
-1
kB55;Gwl Dephosphorylation of Gwl by PP2A:B55 496 min
-1
kB55;Sub Dephosphorylation of the substrate by PP2A:B55 0.06 min
-1
kCdk2;Gwl Phosphorylation of Gwl by Cdk2 0.19 min
-1
kCdc25S Dephosphorylation of Y15 of Cdk1 by unphosphorylated Cdc25 0.005 min
-1
kCdc25F Dephosphorylation of Y15 of Cdk1 by phosphorylated Cdc25 0.94 min
-1
kWee1S Phosphorylation of Y15 of Cdk1 by phosphorylated Wee1 0.005 min
-1
kWee1F Phosphorylation of Y15 of Cdk1 by unphosphorylated Wee1 47 min
-1
kCdk1;Wee1 Phosphorylation of Wee1 by Cdk1:CycB 1.31 min
-1
kCdk1;Cdc25 Phosphorylation of Cdc25 by Cdk1:CycB 1.31 min
-1
kPPX;Y15 Dephosphorylation of Wee1 and Cdc25 by a constitutive phosphatase 0.005 min
-1
kCdk2;Wee1 Phosphorylation of Wee1 by Cdk2 0.11 min
-1
kCdk2;Cdc25 Phosphorylation of Cdc25 by Cdk2 0.11 min
-1
kB55;Wee1 Dephosphorylation of Wee1 by PP2A:B55 0.55 min
-1
kB55;Cdc25 Dephosphorylation of Cdc25 by PP2A:B55 0.55 min
-1
Kd Dissociation constant for 1NM-PP1 with Cdk1 0.025 min
-1Initial conditions correspond to interphase arrest.Dynamic variable Initial value
Subp 0
CycB : Cdk1 0
PP1 1
pENSATot 0
Gwlp 0
(Continued on next page)
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Continued
Dynamic variable Initial value
PP2AB55 0.25
Wee1 1
Wee1pp 0
Cdc25 1
Cdc25pp 0XPPAUT code for the bifurcation diagrams of Figure 3C, Figure S3E, and Figure S4A.
Subp’ = kcBc1Sub*CycBCdk1/((1 + (InhCDK/Kd)))*(SubT-Subp) - kB55Sub*PP2AB55*Subp
CycBCdk1’ = V25*(CycBCdk1T - CycBCdk1) - Vwee*CycBCdk1
PP1’ = (kapp1 + kapp1a*PP1)*(PP1T - PP1) - (kipp1 + kipp1C*CycBCdk1/((1 + (InhCDK/Kd))))*PP1
pENSAt’ = VGwl*(ENSAtot - pENSAt) - kcatB55*Complex
Gwlp’ = (kcBc1G*CycBCdk1/((1 + (InhCDK/Kd))) + kcAc2G*CycACdk2T)*(Gwtot - Gwlp) - (kB55G*PP2AB55 + kppxGwl +
kPP1Gw*PP1)*Gwlp
PP2AB55’ = kdis*Complex + kcatB55*Complex - kass*PP2AB55*(pENSAt - Complex)
Complex = B55tot - PP2AB55
Wee1’ = (kppxY15 + kB55W1*PP2AB55)*Wee1p - (kcBc1W1*CycBCdk1/((1 + (InhCDK/Kd)))y
+ kcAc2W1*CycACdk2T)*Wee1
Wee1pp’ = (kcBc1W1*CycBCdk1/((1 + (InhCDK/Kd))) + kcAc2W1*CycACdk2T)*Wee1p -y
(kppxY15 + kB55W1*PP2AB55)*Wee1pp
Wee1p = 1 - Wee1 - Wee1pp
Cdc25’ = (kppxY15 + kB5525*PP2AB55)*Cdc25p - (kcBc125*CycBCdk1/((1 + (InhCDK/Kd))) + kcAc225*CycACdk2T)*Cdc25
Cdc25pp’ = (kcBc125*CycBCdk1/((1 + (InhCDK/Kd))) + kcAc225*CycACdk2T)*(Cdc25p) -y
(kppxY15 + kB5525*PP2AB55)*Cdc25pp
Cdc25p = 1 - Cdc25 - Cdc25pp
Vwee = (kweeS*(1-Wee1) + kweeF*Wee1)
V25 = k25S*(1-Cdc25pp) + k25F*Cdc25pp
VGwl = kGwENSA*Gwlp
init Subp = 0, CycBCdk1 = 0, PP1 = 1, pENSAt = 0, Gwlp = 0, PP2AB55 = 0.25, Wee1 = 1, Wee1pp = 0, Cdc25 = 1, Cdc25pp = 0
p InhCDK = 1, CycBCdk1T = 8.1808, CycACdk2T = 1.0000, PP1T = 1.0000, kapp1 = 0.0115
p kapp1a = 0.7054, kipp1 = 0.0018, kipp1C = 0.7549, kPP1Gw = 18.4724
p ENSAtot = 1.0000, B55tot = 0.2500, SubT = 1.0000, kass = 617.2807
p kdis = 0.0088, kcatB55 = 1.0338, kGwENSA = 20.8811, kppxGwl = 0.1560, kcBc1Sub = 0.0080
p kcBc1G = 0.2393, Gwtot = 1.0000, kB55G = 496.5636, kB55Sub = 0.0593
p kcAc2G = 0.1916, k25S = 0.0050, k25F = 0.9411, kweeS = 0.0050, kweeF = 47.2937
p kcBc1W1 = 1.3132, kcBc125 = 1.3132, kppxY15 = 0.0050, kcAc2W1 = 0.1096
p kcAc225 = 0.1096, kB55W1 = 0.5511, kB5525 = 0.5511, Kd = 0.025
@ total = 1000,dt = 0.1,meth = STIFF,xlo = 0,xhi = 100,ylo = 0,yhi = 1
@ NTST = 15,NMAX = 1000000,NPR = 10000,DS = 0.001
@ DSMAX = 0.005,DSMIN = 0.001,PARMIN = 0,PARMAX = 10
@ AUTOXMIN = 0,AUTOXMAX = 0.8,AUTOYMIN = 0,AUTOYMAX = 1
donePreparation of total cell extracts, immunoblotting
For cell lysate preparation 53 10E5 cells were washed once in PBS and lysed in 50 mL ECB buffer (50 mM Tris pH 7.5, 120 mMNaCl,
0.5%NP40, 1 mMEDTA, 0.05% b-mercaptoethanol and protease (1 tablet per 50ml) and phosphatase (1 tablet per 10 ml) inhibitors,
and incubated on ice for 20min. Cells were sonicated. Protein concentrations were determined by Bradfordmethod and lysates were
equalized for protein concentration using ECB buffer. Samples were then resuspended in 1 3 SDS–PAGE sample buffer (12.5 mM
Tris–HCl pH 6.8, 1.4% (w/v) SDS, 4% sucrose (w/v), 0.002% (w/v) bromophenyl blue, 0.4 mM b-mercaptoethanol). Samples were
then analyzed by western blotting.
siRNA transfections
Cells were reverse transfected with 20 nM siRNA at a density of 0.4 3 105 cells/ml using Dharmafect 1 transfection reagent
(Dharmacon) following the manufacturers’ protocol. Eight hours following transfection the medium was changed and cells wereCurrent Biology 28, 3824–3832.e1–e6, December 3, 2018 e5
synchronized with 1NM-PP1 24 hours later. Control and Greatwall siRNA (MASTL 06, 50ACGCCTTATTCTAGCAAATTA30) were
purchased from QIAGEN.
FACS analysis
Cells were incubated with 10 mM of EdU for 1h before being harvested and fixed in 70% ethanol. Next, EdU was labeled with the
fluorophore Alexa 647 using Click-iT EdU Imaging Kit (Invitrogen) and DNA were stained with 5 mg/mL of propidium iodide (Fluka)
and 150 mg/mL of RNaseA (Sigma-Aldrich). Facs profiles were obtained from data acquired on Accuri C6 Flow cytometer (BD
Biosci-ences).
Immunofluorescence and live cell imaging
HeLa cdk1as cells were grown on coverslips and fixed for 10min in 3.7% formalde-hyde, rinsed 3 times in PBS. Coverslips were then
rinsed in PBS and cells permeabilized in PBS-0.1% NP40. Cells were blocked in 2% BSA for 10 min and probed with primary anti-
bodies (as indicated in figure legends) for 40 min. Slides/coverslips were rinsed 4 3 in PBS and probed with Alexa secondary anti-
bodies listed for 20min. Slides/coverslips were then rinsed 43 in PBS and coverslips weremounted using ProLongGold mounting
solution containing DAPI (Invitrogen). For image acquisition, we used a Olymnpus IX73 microscope. Imaging was performed using a
UPLanS Apo, N.A. 1.43, 3 60 oil immersion objective (Olympus), standard filter sets (excitation 360/40; 490/20; 555/28; emission
457/50; 528/38; 617/40) and a Prime sCMOS camera (Photometrics). Z-series of 0.7 mm stacks were acquired using Micromanager
software (Version 6.0.8) and images exported as tiff files. Images were analyzed in ImageJ. Regions were manually marked on the
image for analysis and analyzed using the ImageJ ROI manager tool. Live cell imaging was performed on the Olympys IX73
microscope equipped with an environmental chamber (Digital Pixel), using either a 0.6NA 40x PlanFL long distance objective suitable
for differential interference contracts imaging, or a 20x 0.45NA PlanFL long distance objective designed for phase contrast image
acquisition in the wide field channel. Images were acquired using Micromanager software (Version 6.0.8) and recorded by a Prime
sCMOS camera at 37C Temperature and 5% CO2. Environmental conditions were maintained by an environmental chamber from
Digital Pixel.
Bistability Assay
HeLa cdk1as cells were plated at a density of 7500 cells into 96 well half area high content imaging glass bottom microplates
(Corning, 4580). U2OS cdk1as cells were plated in 96 well plates (Perkin Elmer Cell carrier- 96 Ultra) that were coated with 40 mL
of a 1/10 dilution in PBS of Collagen1 (Pan Biotech) and left to dry in a tissue culture hood. Before plating cells, collagen was activated
by washing with PBS two times. Cells were plated at the same density as HeLa cdk1as cells. 24 hours later medium was changed
to medium containing 2 mM 1NM-PP1. Following 20 hour 1NM-PP1 incubation the mitotic exit samples were washed 5 times with
medium, following the last wash 50 ml medium containing 25 mM MG231 was added. 90 minutes later the mitotic exit samples
were washed in the same way and released in 25 mMMG231 medium. Finally, 50 ml medium with 25 mMMG231 and 2x concentra-
tions of the indicated inhibitors was added. Cells were fixed after a further four hour incubation by adding 10 ml 3.4% Formaldehyde
for 10 minutes. Subsequently the fixation medium was removed and resuspended in PBS containing 2 mM Hoechst 33342
(Thermofisher). Imaging was performed on a Olympus IX81 SCANR microscope using a 0.4 NA PlanFL 20x long distance objective,
with a camera ORCA-R2(Hamamatsu CCD). Nuclei were segmented using a bespoke SCANR algorithm based on pixel intensity and
100 random nuclei per well were displayed using the SCANR gallery tools and counted manually.
Automated measurement of mitotic index in live cell experiments
We developed a bespoke MATLAB script to count the number of mitotic cells in a time lapse experiment. This is based on estimating
the total number of cells in the field of view based on segmentation of the sirDNA stained nuclei using a standard Otsu algorithm [41].
Mitotic cells were detected by the change in intensity in the phase contract channel during cell rounding. To identify the resulting
bright halo circles in the segmentation, we employed an algorithm based on a circular Hough Transform [42] and filtered the identified
objects by circularity and size.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments included at least three independent biological repeats. Sample size per repeat varied between experiments and are
indicated in the Figure Legends as well as Mean, Standard Deviation or Median values. Sample size was based on standard practise
in cell biological assays and not specifically pre-estimated. P values were calculated using a 1 tail unequal variance t test. For all
experiments, samples were not randomized and the investigators were not blinded to the group allocation during experiments
and outcome assessment. No exclusion criteria were used and all collected data were used for statistical analysis.e6 Current Biology 28, 3824–3832.e1–e6, December 3, 2018
